|
|
|
11 of 11 Flu Shots / Flu Mist |
|
|
|
 |
| Afluria Single Dose |  |
|
|
Contains Mercury: | no mercury
| |
Patient Age: | 18 years and older
| |
Shot or Mist: | shot
| |
Manufacturer: | CSL
| |
Brand: | Afluria
| |
Safe If Pregnant: | consult your physician
| |
|
|
|
|
|
|
|
|
 |
Afluria® is indicated for active immunization of persons 18 years of age and older against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. The indication is based on the immune response elicited by Afluria®; no controlled clinical studies have demonstrated a decrease in influenza disease after vaccination with Afluria®.
Afluria® should not be administered to individuals with hypersensitivity to eggs or chicken protein or other components of Afluria®, or to anyone who has had a life-threatening reaction to previous influenza vaccination. The most common injection-site adverse reactions were tenderness, pain, redness, and swelling. The most common systemic adverse reactions were headache, malaise, and muscle aches.
Indications And Usage
AFLURIA® is an inactivated influenza virus vaccine indicated for active immunization of persons ages 18 years and older against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. This indication is based on the immune response elicited by AFLURIA®; there have been no controlled clinical studies demonstrating a decrease in influenza disease after vaccination with AFLURIA®.
Contraindications
AFLURIA® is contraindicated in individuals with known hypersensitivity to eggs or chicken protein, neomycin, or polymyxin, or in anyone who has had a life-threatening reaction to previous influenza vaccination.
Warnings And Precautions
- If GBS has occurred within 6 weeks of previous influenza vaccination, the decision to give AFLURIA® should be based on careful consideration of the potential benefits and risks.
- If AFLURIA® is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the immune response may be diminished.
- Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.
- Vaccination with AFLURIA® may not protect all individuals.
Pregnancy
It is not known whether AFLURIA® can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. AFLURIA® should be given to a pregnant woman only if clearly needed.
Nursing Mothers
AFLURIA® has not been evaluated in nursing mothers. It is not known whether AFLURIA® is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when AFLURIA® is administered to a nursing woman.
|
|
Dosage Information:
0.5 mL preservative-free, single-dose, pre-filled syringe.
Each 0.5 mL dose contains 15 mcg of influenza virus hemagglutinin (HA) from
each of the three strains: A/Solomon Islands/3/2006 (H1N1), A/Wisconsin
/67/2005 (H3N2), and B/Malaysia/2506/2004.
|
|
|
|
|
